InnoCore Pharmaceuticals Enters into Exclusive License Agreement with Allergan
Related to Development of New Medicines for Ophthalmic Diseases
GRONINGEN, The Netherlands, October 22, 2013
GRONINGEN, The Netherlands, October 22, 2013 /PRNewswire/ --
InnoCore Pharmaceuticals today announced that it has signed an exclusive
License and Collaboration Agreement with Allergan, Inc. (NYSE: AGN), a
multi-specialty health care company headquartered in Irvine, California.
Under the agreement, the companies will expand their existing collaboration
and jointly continue to develop long-acting ocular drug delivery products for
the treatment of ophthalmic diseases. Utilizing its patented SynBiosys®
polymeric drug delivery platform, InnoCore will formulate Allergan's
proprietary drugs into pharmaceutical products expected to be capable of
sustained release for many months following a single ocular injection. The
SynBiosys® drug delivery platform is based on novel biodegradable multi-block
co-polymers with unique molecular architectures that allow precise and
site-specific delivery of drugs for predetermined periods of time, ranging
from weeks to many months.
Jan Hendriks, Chief Executive Officer of InnoCore Pharmaceuticals commented:
"We are very excited that we have expanded this important partnership with
Allergan, a company that is widely recognized as a leading company in the
development of controlled release ophthalmology medicines. Expanding our
partnership with Allergan is a great opportunity for us to further grow
InnoCore in line with our ambitions."
About InnoCore Pharmaceuticals:
InnoCore Pharmaceuticals is a specialty pharmaceutical company focused on the
development and manufacturing of long acting injectable drug delivery products
for the treatment of chronic diseases. Utilizing its proprietary drug delivery
technologies such as its unique SynBiosys® polymer platform, InnoCore develops
biodegradable sustained release depots for precisely controlled delivery of
therapeutic compounds. Depot technologies include microspheres, solid
implants, coatings and gels.
Since its inception in 2003, InnoCore has successfully established
partnerships with biomedical, biotech and pharmaceutical companies throughout
the world to develop sustained release depot formulations for small molecules,
peptides and therapeutic proteins, including long-acting specialty generics.
Over the years InnoCore's versatile SynBiosys® platform has shown its safety
and effectiveness in several pre-clinical and clinical trials. Earlier this
year, the first product with InnoCore's SynBiosys® drug delivery technology
incorporated received regulatory approval and is now available in the clinic.
InnoCore Pharmaceuticals is privately owned and is located in Groningen, The
Netherlands. For more information about InnoCore Pharmaceuticals, please visit
our website http://www.innocorepharma.com .
Allergan is a multi-specialty health care company established more than 60
years ago with a commitment to uncover the best of science and develop and
deliver innovative and meaningful treatments to help people reach their life's
potential. Today, we have approximately 11,200 highly dedicated and talented
employees, global marketing and sales capabilities with a presence in more
than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals,
biologics, medical devices and over-the-counter consumer products, and
state-of-the-art resources in R&D, manufacturing and safety surveillance that
help millions of patients see more clearly, move more freely and express
themselves more fully. From our beginnings as an eye care company to our focus
today on several medical specialties, including eye care, neurosciences,
medical aesthetics, medical dermatology, breast aesthetics, obesity
intervention and urologics, Allergan is proud to celebrate more than 60 years
of medical advances and proud to support the patients and customers who rely
on our products and the employees and communities in which we live and work.
For more information regarding Allergan, go to: http://www.allergan.com .
This press release contains "forward-looking statements", including but not
limited to statements regarding development plans, the SynBiosys ® drug
delivery platform, and product candidates and related capabilities. These
statements are based on current expectations of future events. If underlying
assumptions prove inaccurate or unknown risks or uncertainties materialize,
actual results could vary materially from current expectations and
projections. The parties expressly disclaim any intent or obligation to update
these forward-looking statements except as required by law.
For further information, please contact us: Phone:+31(0)50-575-3100,Email:
Press spacebar to pause and continue. Press esc to stop.